Phaseline

Targets › ALDH2

ALDH2 (Aldehyde dehydrogenase, mitochondrial): drug programs, companies and trials

6 programs from 6 companies in 6 trials: 3 Phase 1, 2 Phase 2, 1 Phase 3; Oncology, Ophthalmology, Neurology; next expected readout Dec 2026.

Mitochondrial aldehyde dehydrogenase with broad substrate specificity which participates in the detoxification of ethanol-derived acetaldehyde and endogenous aldehydes, including those arising from lipid peroxidation. The reaction mechanism involves a nucleophilic attack on the aldehyde substrate, resulting in formation of a thiohemiacetal intermediate. (UniProt, P05091)

Open in Phaseline: the race on ALDH2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Peking Union Medical College HospitalEdaravone Dexborneol Sublingual Tablets
Free radical scavenger and neuroprotectant (Edaravone); vasodilator and cerebral blood flo
ALDH2Phase 3Cerebral Small Vessel DiseaseOct 2027
Foresee PharmaceuticalsMirivadelgat
Selective aldehyde dehydrogenase 2 (ALDH2) activator
ALDH2Phase 2Group 3 Pulmonary HypertensionFeb 2028
Memorial Sloan Kettering Cancer CenterDisulfiram
Aldehyde dehydrogenase inhibitor
ALDH2Phase 2OsteosarcomaMar 2028
Case Comprehensive Cancer CenterDisulfiram
Aldehyde dehydrogenase inhibitor
ALDH2Phase 1Relapsed SarcomasDec 2026
University of WashingtonDisulfiram
Aldehyde dehydrogenase inhibitor
ALDH2Phase 1Inherited Retinal Dystrophy Primarily Involving Sensory RetinaFeb 2027
University of Rochesterdisulfiram
Aldehyde dehydrogenase inhibitor
ALDH2Phase 1Alcohol Use DisorderMay 2029

Conditions

Relapsed Sarcomas (1) Inherited Retinal Dystrophy Primarily Involving Sensory Retina (1) Cerebral Small Vessel Disease (1) Osteosarcoma (1) Group 3 Pulmonary Hypertension (1) Alcohol Use Disorder (1)

Modalities

small molecule (6)

Companies

Case Comprehensive Cancer Center (1) University of Washington (1) Peking Union Medical College Hospital (1) Memorial Sloan Kettering Cancer Center (1) Foresee Pharmaceuticals (1) University of Rochester (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.